International Ophthalmology

, Volume 16, Issue 4–5, pp 349–353 | Cite as

Dopamine, dopaminergic drugs and ocular hypertension

  • M. Virno
  • A. Gazzaniga
  • L. Taverniti
  • J. Pecori Giraldi
  • F. De Gregorio
Section 8: Medical Treatment

Abstract

The study refers to the clinical experiences performed with several D1 and D2 dopaminergic receptors agonists in 20 patients with high tension open angle glaucoma. The substances were administered topically as eye drops as well as an ocular eye bath. The parameter examined was intraocular pressure (IOP). The substances taken in consideration were: Dopamine, Ibopamine (dopamine analog), Fenoldopam and 3B90 (D1-receptor agonists) and Bromocriptine (dopaminergic agonist with higher affinity for D2 than for D1-receptors). It has been shown that all selective D1-receptors agonists induce a significant increase in IOP only in eyes with hydrodynamic disorders (p<0.001). Such hypertensive effects could not be antagonized either by topically administered dopaminergic antagonists (Sulpiride, D2-receptors antagonist, and Haloperidol, non-selective dopaminergic antagonist) or by the pretreatment with the commonly used topical antiglaucomatous drugs. The only substance which proved able to inhibit the IOP increase induced by the D1-receptors agonists was the D1-selective antagonist SCH-23390, suggesting that IOP increase may be a result of a stimulation of the D1-receptors. The authors hypothesize that dopaminergic system may play a role in the regulation of aqueous humor hydrodynamics.

Key words

dopamine dopaminergic agonists dopaminergic antagonists IOP glaucoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Asagrande C, Ghirardi P, Marchetti G. Ibopamine. In: Scriabine A, editor. New drugs annual: cardiovascular drugs. New York: Raven Press, 1985; 3: 173–96.Google Scholar
  2. 2.
    Virno M, Taverniti L, Motolese E, Taloni M, Bruni P, Pecori Giraldi J. Ibopamina, nuovo midriatico non cicloplegico (nota preliminare). Boll Ocul 1986; 44: 1135–46.Google Scholar
  3. 3.
    Virno M, Taverniti L, Taloni M, Ioppolo A, Pellegrino N. Studio sperimentale degli effetti locali e sistemici dell'ibopamina, farmaco dotato di attività adrenergica e dopaminergica. Boll Ocul 1986; 44: 1169–85.Google Scholar
  4. 4.
    Virno M, Pecori Giraldi J, Taverniti L, Taloni M, Pannarale L. Intraocular effects of topical administered ibopamine in eyes with hydrodynamic disorders: a new provocative test for glaucoma. Glaucoma 1990; 12: 88–92.Google Scholar
  5. 5.
    Virno M, Cozza R, Taloni M, Terrana M. Indagini sui comportamento del tono oculare dopo ibopamina in pazienti con neurotticopatia senza ipertensione. Acta LXVII Congr Soc Oftalm, Italiana, Cappelli Editore 1987: 219.Google Scholar
  6. 6.
    Virno M, Pecori Giraldi J, Garofalo G, Grechi G, De Angelis D, Pannarale MR. L'ibopamina come test di provocazione nel glaucoma sine ipertensione. Boll Ocul 1991; 49 suppl 1: 187.Google Scholar
  7. 7.
    Virno M, De Gregorio F, Grechi G, Da Dalt S. Comportamento della pressione oculare e della motilità pupillare dopo somministrazione topica di ibopamina 2% in soggetti sani. Boll Ocul 1991; 49 suppl 1: 239.Google Scholar
  8. 8.
    Rolle T, Brogliatti B, Valvo G, Boles Carenini B. Uso dell'ibopamina nell'iter diagnostico del glaucoma cronico ad angolo aperto. Boll Ocul 1991; 49 suppl 1: 247.Google Scholar
  9. 9.
    Boles Carenini A, Valvo G, Sibur G, Rolle T, Brogliatti B. Variazioni del flusso ematico oculare prima e dopo instillazione di ibopamina. Boll Ocul 1991; 49 suppl 5: 297.Google Scholar
  10. 10.
    Boles Carenini B, Brogliatti B, Rolle T, Valvo G. Ibopamina: studi tonografici. Boll Ocul 1991; 49 suppl 5: 311.Google Scholar
  11. 11.
    Lodi M, Novella L, Marras A, Cambiaggi A. Il test all'ibopamina in occhi portatori di sindrome della pseudoesfoliazione. Boll Ocul 1992; 50 suppl 2: 111.Google Scholar
  12. 12.
    Nuti A, Menicacci F, Ciappetta R, Diadori A. Nostre esperienze sull'utilizzazione del test alPibopamina in pazienti sottoposti ad argon laser trabeculoplastica. Boll Ocul, in press.Google Scholar
  13. 13.
    Giordano G, Venzano D, Rolando M, Calabria G. Ibopamina e pressione intraoculare. Boll Ocul 1991; 49 suppl 1: 209.Google Scholar
  14. 14.
    Chiou GCY, Chiou FY. Dopaminergic involvement in intraocular pressure in the rabbit eye. Ophthalmic Res 1983; 15: 131–5.Google Scholar
  15. 15.
    Chiou GCY. Treatment of ocular hypertension and glaucoma with dopamine antagonists. Ophthalmic Res 1984; 16: 129–34.Google Scholar
  16. 16.
    Chiou GCY. Ocular hypotensive action of haloperidol, a dopaminergic antagonist. Arch Ophthalmol 1984; 102: 143–5.Google Scholar
  17. 17.
    Chiou GCY, Chiou FY. Effects of dopaminergic antagonists injected through vortex veins on intraocular pressure. J Ocular Pharmacology 1989; 5: 281–291.Google Scholar
  18. 18.
    Karnezis TA, Tripathi BJ, Dawson G, Murphy MB, Tripathi RC. Effects of dopamine receptors activation on the level of c-AMP in trabecular meshwork. Inv Ophthal Vis Sci 1989; 30: 1090–1094.Google Scholar
  19. 19.
    Karnezis TA, Murphy MB. Dopamine receptors and intraocular pressure. Trends Pharmacol Sci 1988; 9: 389–90.Google Scholar
  20. 20.
    Karnezis TA, Murphy MB, Weber RR, Nelson KS, Tripathi BJ, Tripathi RC. Effects of selective dopamine-1 receptor activation on intraocular pressure in man. Exp Eye Res 1988; 47: 689–97.Google Scholar
  21. 21.
    Leopold IH, Duzman E. Observations on the pharmacology of Glaucoma. Ann Rev Pharmacol Toxicol 1986; 26: 401–26.Google Scholar
  22. 22.
    Mekki QA, Warrington SJ, Turner P. Bromocriptine eyedrops lower intraocular pressure without affecting prolactine levels. Lancet 1984; 1: 287–288.Google Scholar
  23. 23.
    Potter DE, Rowland JM. Adrenergic drugs and intraocular pressure, effects of selective beta-adrenergic agonists. Exp Eye Res 1978; 27: 615–25.Google Scholar
  24. 24.
    Potter DE, Burke JA. Effects of ergoline derivatives on intraocular pressure and iris function in rabbits and monkeys. Curr Eye Res 1982/83; 2: 281–288.Google Scholar
  25. 25.
    Potter DE, Burke JA, Chang FW. Alteration in ocular function induced by phenylthylamine analogs of dopamine. Curr Eye Res 1984; 3: 851–859.Google Scholar
  26. 26.
    Potter DE, Burke JA, Chang FW. Ocular hypotensive action of ergoline derivatives in rabbits: effects of sympathectomy and domperidone pretreatment. Curr Eye res 1984; 3: 307–314.Google Scholar
  27. 27.
    Shannon R, Head A, Sears ML. The effect of dopamine on the intraocular pressure and pupil of the rabbit eye. Invest Ophthalm 1976; 15: 371–80.Google Scholar
  28. 28.
    Macri FJ, Cevario SJ. The inhibitory action of dopamine, hydroxyamphetamine and phenylephrine on aqueous humor formation. Exp Eye Res 1978; 26: 85–9.Google Scholar
  29. 29.
    McLaughlin MA, Chiou GCY. A synopsis of recent developments in antiglaucoma drugs. J Ocular Pharmacol 1985; 1: 101–21.Google Scholar
  30. 30.
    Al-Sereiti MR, Turner P. The effect of lisuride, terguride, and bromocriptine on intraocular pressure. Br J Clin Pharmacol 1989; 27: 159–63.Google Scholar
  31. 31.
    Langer SZ. The regulation of transmitter release elicited by nerve stimulation through a presynaptic feed-back mechanism. In: Usdin E, Snyder SH, editors. Frontiers in Catecholamines Research. Pergamon, London, 1973: 543–9.Google Scholar
  32. 32.
    McCulloch MW, Rand MJ, Story DF. Evidence for a dopaminergic mechanism for modulation of adrenergic transmission in the rabbit ear artery. Br J Pharmacol 1973; 49: 141–2.Google Scholar
  33. 33.
    Green K, Hensley A, Lollis G. Dopamine stimulation of passive permeability and secretion in the isolated rabbit epithelium. Exp Eye Res 1979; 29: 423–7.Google Scholar
  34. 34.
    Piltz JR, Stone RA, Audet P, Boike S, Everitt D, Shusterman NH, Jorkasky D. Fenoldopam, a selective Dopamine-1 receptor agonist, raises intraocular pressure in man. ARVO Abstract 1992; 33(4): 1121.Google Scholar
  35. 35.
    Hariton C. Implication des récepteurs dopaminergiques dans la régulation de la pression intraoculaire. Clinique Ophthalmol 1991; 1: 97–102.Google Scholar
  36. 36.
    Virno M, De Gregorio F, Grechi G, Sedran L, Trimarchi M. Azione dell'ibopamina sulla dinamica dell'umore acqueo: indagine fluorofotometrica. Boll Ocul 1992; 50 suppl 2: 107.Google Scholar

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • M. Virno
    • 1
  • A. Gazzaniga
    • 1
  • L. Taverniti
    • 1
  • J. Pecori Giraldi
    • 1
  • F. De Gregorio
    • 1
  1. 1.Department of Ocular Physio-Pharmacology, Institute of OphthalmologyUniversity of Rome ‘La Sapienza’RomeItaly

Personalised recommendations